Phase I Platinum Based Chemotherapy Plus Indomethacin
Ontology highlight
ABSTRACT: Mesenchymal stem cells (MSCs) are present in the circulation of cancer patients, and are recruited to the stroma of both the primary tumor and metastasis. Recent preclinical research has shown that in response to platinum-based chemotherapy, MSCs secrete two specific platinum-induced fatty acids (PIFAs) which induce resistance to a broad spectrum of chemotherapies. The secreted PIFAs are the fatty acid oxo-heptadecatetraenoic acid (KHT) and the omega-3 fatty acid hexadecatetraenoic acid (16:4). These PIFAs are produced via the COX-1 pathway. COX inhibitors, including indomethacin. This phase 1 study explores the safety of combining indomethacin with platinum containing chemotherapy.
DISEASE(S): Esophageal Neoplasms,Colorectal Neoplasms,Ovarian Neoplasms,Neoplasms
PROVIDER: 2134582 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA